Filana Therapeutics, Inc.
$1.75
▲
0.58%
2026-04-21 06:52:01
www.filanatx.com
NCM: FLNA
Explore Filana Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$84.54 M
Current Price
$1.75
52W High / Low
$2.27 / $1.53
Stock P/E
—
Book Value
$1.54
Dividend Yield
—
ROCE
-128.99%
ROE
-82.66%
Face Value
—
EPS
$-1.88
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
-0.68
Debt / Equity
—
Current Ratio
2.23
Quick Ratio
2.23
Forward P/E
—
Price / Sales
—
Enterprise Value
$-16.28 M
EV / EBITDA
0.28
EV / Revenue
—
Rating
None
Target Price
$8
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lexeo Therapeutics, Inc. | $6.53 | — | $511.94 M | — | -85.23% | -55% | $10.99 / $2.19 | $3.38 |
| 2. | Vivani Medical, Inc. | $1.51 | — | $127.82 M | — | -84.04% | -1.6% | $1.92 / $0.92 | $0.21 |
| 3. | Inhibikase Therapeutics, Inc. | $1.81 | — | $238.98 M | — | -30.85% | -36.04% | $2.37 / $1.33 | $1.02 |
| 4. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
| 5. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 6. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 7. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -14.29 M | -11.86 M | -45.39 M | -24.59 M | -30.32 M |
| Net Profit | -12.54 M | -10.81 M | -44.22 M | -23.4 M | -27.6 M |
| EPS in Rs | -0.26 | -0.22 | -0.92 | -0.48 | -0.57 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -96.13 M | -142.28 M | -107.33 M | -81.48 M |
| Net Profit | -90.97 M | -24.34 M | -97.22 M | -76.25 M |
| EPS in Rs | -1.88 | -0.5 | -2.01 | -1.58 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 118.36 M | 157.53 M | 151.66 M | 234.83 M |
| Total Liabilities | 43.95 M | 11.83 M | 14.2 M | 7.29 M |
| Equity | 74.4 M | 145.7 M | 137.47 M | 227.54 M |
| Current Assets | 97.71 M | 136.53 M | 129.63 M | 211.23 M |
| Current Liabilities | 43.83 M | 11.75 M | 14.2 M | 7.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -32.25 M | -116.93 M | -82.03 M | -77.51 M |
| Investing CF | -0.58 M | -0.1 M | -0.41 M | -2.71 M |
| Financing CF | -0.24 M | 124.47 M | 2.56 M | 47.8 M |
| Free CF | -32.83 M | -117.03 M | -82.44 M | -80.23 M |
| Capex | -0.58 M | -0.1 M | -0.41 M | -2.71 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 74.96% | -27.5% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.